ToxiBenzo | Instant Benzodiazepine Withdrawal Scoring Tool (CIWA-B)

ToxiBenzo is designed for clinicians, toxicologists, emergency physicians, hospitalists, psychiatrists, addiction medicine teams, ICU providers, and pharmacists managing benzodiazepine withdrawal in inpatient, emergency, detox, or medically supervised taper settings.

You’ll need bedside inputs for CIWA-B, including observed findings (restlessness/agitation, tremor, sweating) and patient-reported symptoms (anxiety, irritability, sleep quality, sensory disturbances, concentration difficulties, autonomic symptoms, and somatic complaints). Benzodiazepine exposure history (agent, daily dose, duration, and time since last dose) helps interpret risk and support taper planning.

ToxiBenzo suggests guideline-informed options for withdrawal management, including severity-based monitoring cadence, safety checks, and taper frameworks (including when to slow/hold/escalate). Final decisions must be made by the treating provider using clinical judgment and local protocols.

Use caution. CIWA-B scoring may be confounded by mixed intoxication (e.g., stimulants, anticholinergics), delirium, alcohol co-withdrawal, opioid withdrawal, sedative co-withdrawal, acute psychiatric decompensation, or major medical illness. In these cases, ToxiBenzo can support structured symptom tracking, but severity classification and suggested actions may not reflect the true clinical driver.

It can help standardize assessment, but special populations (older adults, hepatic impairment, respiratory disease, pregnancy, frailty, delirium risk) often require individualized medication selection, slower tapers, and closer monitoring. Follow institution-specific guidance and consult specialists when appropriate.